Bedaquiline + Pretomanid + Linezolid (BPaL Regimen)
Treatment for HIV/AIDS - Extensively drug-resistant Tuberculosis
Typical Dosage: Bedaquiline: 400mg daily (2 weeks), then 200mg 3x/week (22 weeks); Pretomanid: 200mg daily; Linezolid: 600mg daily (often reduced to 300mg)
Effectiveness
88%
Safety Score
38%
Clinical Trials
12
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
38
DangerousModerateSafe
Treatment Details
Dosage Range
Bedaquiline: 400mg daily (2 weeks), then 200mg 3x/week (22 weeks); Pretomanid: 200mg daily; Linezolid: 600mg daily (often reduced to 300mg)
Time to Effect
2-4 weeks (sputum conversion), 1-2 months (clinical improvement)
Treatment Duration
6-9 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$4,000
Side Effect Mgmt:$5,000
Total Annual:$49,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$6,125/QALY
QALYs Gained
8
Outcome-Based Costs
Cost per Responder
$55,682
Cost per Remission
$55,682
Comparison vs Longer-course XDR-TB regimen (e.g., individualized regimen with injectables, up to 24 months)
Cost Difference
$-5,000/year
Less expensive
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Bedaquiline + Pretomanid + Linezolid (BPaL Regimen) Outcomes
for HIV/AIDS - Extensively drug-resistant Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+88%
Remission Rate
+88%
Common Side Effects
Peripheral neuropathy
+60%
Myelosuppression (anemia, thrombocytopenia)
+25%
Hepatotoxicity
+20%
QT prolongation
+15%
Optic neuropathy
+5%
Gastrointestinal disturbances
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov